Basking Biosciences Takes Major Step with BB-025 Phase 1 Study to Reverse Stroke Treatment BB-031 Basking Biosciences has commenced a pivotal Phase 1 study for BB-025, a groundbreaking reversal agent for BB-031, aimed at enhancing stroke treatment efficacy and safety.

Basking Biosciences Takes Major Step with BB-025 Phase 1 Study to Reverse Stroke Treatment BB-031 #Basking_Biosciences #BB-031 #BB-025

Basking Biosciences Advances Innovative Stroke Treatment with New CEO and Funding for Clinical Trials Basking Biosciences has initiated its Phase 2 stroke trial, appointed Dr. Julia C. Owens as CEO, and secured $27.5 million in funding.

Basking Biosciences Advances Innovative Stroke Treatment with New CEO and Funding for Clinical Trials #USA #Research_Triangle #Basking_Biosciences #BB-031 #Julia_Owens